28.45
+0.89%
Close of 9 Nov 2026, in TWD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Chi Sheng Pharma & Biotech Co
Its shares trade on Taipei Exchange under the ticker 4111.TWO. It has been listed since 6 March 1999. In the fiscal year to 31 December 2025, it reported revenue of TWD 1.38bn and net income of TWD 164.3m. At that date it held total assets of TWD 1.94bn and shareholders' equity of TWD 1.38bn.
Chi Sheng Pharma & Biotech Co., Ltd. engages in the manufacture and distribution of medical medicines and equipment. The company is headquartered in Hukou, Hsinchu. The firm provides injections, including hemodialysis concentrate, amino acid injection with electrolytes, vitamins, cephalosporin antibiotics, antihistamines and antipruritics, as well as ginkgo injections; oral preparations, including antibiotics, cold syrups and liquid antacid; external medicines, including contact lens fluid, normal saline for wash and povidone-iodine solution, and consumer goods, including functional health foods, skin care products and cosmetics. The company also provides medical devices and equipment. The firm distributes its products in domestic markets and to overseas markets, including Mainland China and Southeast Asia.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 6 Mar 1999
- Website
- cscp.com.tw ↗
Leadership
Pay as last reported
- Dongmao SuChairman of the Board, General Manager, since 2002
- Wujin DaiDeputy General Manager-International Business & Management
- Huizhen HuangHead of Finance and Accounting, Corporate Governance Officer, since 2023
- Yuanqiong LiDirector
- Rongyao LinDirector
- Xiuying Shen YuDirector
- Yaotang ShiDirector, since 2024
- Dongyu SuDirector
- Jiajun SuDirector
- Yujun SuDirector
- Mingxun XieDirector
- Mingtao FangIndependent Director, since 2018
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Chi Sheng Pharma & Biotech Co Ltd manufactures hemodialysis concentrate and cephalosporin antibiotics in Hukou, Hsinchu.
- The company distributes amino acid injections with electrolytes and ginkgo injections across Southeast Asia markets.
- Chi Sheng Pharma provides functional health foods and skin care products as part of its consumer goods segment.
Weaknesses
- Chi Sheng Pharma & Biotech Co Ltd focuses on domestic markets without expanding to Europe or North America.
- The company's product range includes only medical equipment and not advanced biotech solutions.
- Chi Sheng Pharma's distribution to Mainland China faces potential regulatory challenges.
Opportunities
- Chi Sheng Pharma can expand its ginkgo injection sales into the European market.
- The company has potential to grow its functional health foods segment in Southeast Asia.
- Chi Sheng Pharma can increase its antibiotic distribution in Mainland China markets.
Threats
- Chi Sheng Pharma faces competition from local manufacturers in Southeast Asia markets.
- The company's antihistamine products may encounter regulatory restrictions in Mainland China.
- Chi Sheng Pharma's external medicines like povidone-iodine solution could face supply chain disruptions.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.